Preventing the
Progression
of CNS disorders
by targeting the cellular
damage response
mechanism​​s
damage response
mechanism​​s
Protecting
neurons to fight neurodegenerative diseases.
neurons to fight neurodegenerative diseases.
CT1812, Cognition Therapeutics’ lead product candidate is a once-daily, oral, small-molecule designed to rescue trafficking deficits, a “housekeeping” function that is impaired in neurodegenerative and neuro-ophthalmic diseases.
By binding to the receptor responsible for regulating these functions, CT1812 helps to maintain the normal function of neurons in the brain and eye, potentially slowing progression of Alzheimer’s disease, dementia with Lewy bodies, and dry age-related macular degeneration.
Areas of Focus
Alzheimer’s disease is characterized by an age-related buildup of toxic proteins in the brain, which bind to receptors and disrupt key cellular processes. CT1812, Cognition Therapeutics’ lead product candidate, has been shown to displace toxic protein oligomers that have attached to neurons, potentially restoring normal cellular function.
Watch our mechanism of action video to learn more.
Age-related buildup of toxic proteins is also known to be a cause of dementia with Lewy bodies (DLB), the second most common form of degenerative dementia. CT1812 is believed to help maintain the function of the sigma-2 receptor and has the potential to protect neurons from the two types of pathogenic proteins known to drive the progression of DLB.
In a number of eye diseases, including dry age-related macular degeneration (dry AMD) and geographic atrophy (GA), a more advanced form of the disease, cellular processes within retinal pigment epithelial (RPE) cells are damaged. These cells are then unable to perform their critical role in maintaining healthy photoreceptors, which are necessary for vision. CT1812 is capable of crossing the blood-retinal barrier and has been shown to protect RPE cells from damaging influences.
